Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and Without Aluminum Phosphate or Matrix-M1™ Adjuvants In Clinically-Stable Older Adults
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Jul 2017
At a glance
- Drugs Aluminium phosphate (Primary) ; RSV F protein vaccine-Novavax (Primary) ; Adjuvants
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Novavax
- 24 Jul 2017 Topline data published in a Novavax Media Release.
- 21 Jul 2017 According to a Novavax media release, the company plans to announce topline data from this trial on 24 July 2017 during a conference call and webcast.
- 08 May 2017 According to a Novavax media release, the company expects to announce top-line data from this trial in the next 90 days.